[
  {
    "ts": null,
    "headline": "Stocks Churn as Busy Earnings Week to Test Rally: Markets Wrap",
    "summary": "(Bloomberg) -- Wall Street traders bracing for a deluge of corporate earnings and key economic data sent stocks churning on Monday as they awaited more insights on the impacts of President Donald Trump’s trade war.Most Read from BloombergNewsom Says California Is Now the World’s Fourth-Biggest EconomyAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryLos Angeles Downgraded to AA- by S&P Due to Budget WoesUS Cricket Deepens Bet on Texas With HQ Shift From CaliforniaThe Last Thing U",
    "url": "https://finnhub.io/api/news?id=068217683677097bf96c79dd9b3261221bf57f20be61457d35169a1cde3284dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745852029,
      "headline": "Stocks Churn as Busy Earnings Week to Test Rally: Markets Wrap",
      "id": 134114876,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Wall Street traders bracing for a deluge of corporate earnings and key economic data sent stocks churning on Monday as they awaited more insights on the impacts of President Donald Trump’s trade war.Most Read from BloombergNewsom Says California Is Now the World’s Fourth-Biggest EconomyAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryLos Angeles Downgraded to AA- by S&P Due to Budget WoesUS Cricket Deepens Bet on Texas With HQ Shift From CaliforniaThe Last Thing U",
      "url": "https://finnhub.io/api/news?id=068217683677097bf96c79dd9b3261221bf57f20be61457d35169a1cde3284dd"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): Among the Most Profitable Blue Chip Stocks to Buy Now",
    "summary": "We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other most profitable blue chip stocks to buy now. Blue chip stocks are large, financially stable companies with strong market presence, consistent profitability, […]",
    "url": "https://finnhub.io/api/news?id=2cd3ac309f53b5a00137478d3c6410d15a86c100736f849ca367cb7855afecd4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745873061,
      "headline": "Johnson & Johnson (JNJ): Among the Most Profitable Blue Chip Stocks to Buy Now",
      "id": 134130965,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other most profitable blue chip stocks to buy now. Blue chip stocks are large, financially stable companies with strong market presence, consistent profitability, […]",
      "url": "https://finnhub.io/api/news?id=2cd3ac309f53b5a00137478d3c6410d15a86c100736f849ca367cb7855afecd4"
    }
  },
  {
    "ts": null,
    "headline": "CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug",
    "summary": "Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.",
    "url": "https://finnhub.io/api/news?id=e28053fabe8aec019f8d6a4baed0d5673ca7d57be9f5f758ff3b231ee251dc10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745870756,
      "headline": "CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug",
      "id": 134130966,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.",
      "url": "https://finnhub.io/api/news?id=e28053fabe8aec019f8d6a4baed0d5673ca7d57be9f5f758ff3b231ee251dc10"
    }
  },
  {
    "ts": null,
    "headline": "My 10 Must-Own Dividend Stocks For Your Retirement Portfolio (One Yields 9.65%)",
    "summary": "Discover 10 must-own dividend stocks to boost retirement income. Blend growth, income & appreciation with picks like Microsoft, Visa & Chevron.",
    "url": "https://finnhub.io/api/news?id=e7f58de6c31b636bb72d0a835eb822ea34a52ee7aacaa5c85a9f66845e36a38d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745863200,
      "headline": "My 10 Must-Own Dividend Stocks For Your Retirement Portfolio (One Yields 9.65%)",
      "id": 134119712,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1782231699/image_1782231699.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover 10 must-own dividend stocks to boost retirement income. Blend growth, income & appreciation with picks like Microsoft, Visa & Chevron.",
      "url": "https://finnhub.io/api/news?id=e7f58de6c31b636bb72d0a835eb822ea34a52ee7aacaa5c85a9f66845e36a38d"
    }
  },
  {
    "ts": null,
    "headline": "New data from J&J’s bladder cancer drug-device trial strengthens support for NDA",
    "summary": "J&J submitted a New Drug Application to the FDA for TAR-200 in January 2025.",
    "url": "https://finnhub.io/api/news?id=4ce972342d89ee39ee0bc5d2c8bbf71acbb37cbe4abaeb6f42f812094d86041d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745861767,
      "headline": "New data from J&J’s bladder cancer drug-device trial strengthens support for NDA",
      "id": 134130967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J submitted a New Drug Application to the FDA for TAR-200 in January 2025.",
      "url": "https://finnhub.io/api/news?id=4ce972342d89ee39ee0bc5d2c8bbf71acbb37cbe4abaeb6f42f812094d86041d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference",
    "summary": "Johnson & Johnson will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 10:00 a.m. Eastern...",
    "url": "https://finnhub.io/api/news?id=4cf27f1c19aeb289b0425ff1524987bf32aded983235040699c893c90a8383e8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745857623,
      "headline": "Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference",
      "id": 134118880,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 10:00 a.m. Eastern...",
      "url": "https://finnhub.io/api/news?id=4cf27f1c19aeb289b0425ff1524987bf32aded983235040699c893c90a8383e8"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says Trump Administration Should Intervene in Johnson & Johnson (JNJ) Legal Issues – ‘Where Are Capitalist Instincts Here?’",
    "summary": "We recently published a list of Top 10 Stocks to Watch as Investors Brace for Recession. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other top stocks to watch as investors brace for recession. Despite some optimism in the market after President Donald Trump’s indication […]",
    "url": "https://finnhub.io/api/news?id=bff61708c68805878447a0ffe987fecb43e3677f4601d7f727df6d66d9d81bd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745853611,
      "headline": "Jim Cramer Says Trump Administration Should Intervene in Johnson & Johnson (JNJ) Legal Issues – ‘Where Are Capitalist Instincts Here?’",
      "id": 134115086,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of Top 10 Stocks to Watch as Investors Brace for Recession. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other top stocks to watch as investors brace for recession. Despite some optimism in the market after President Donald Trump’s indication […]",
      "url": "https://finnhub.io/api/news?id=bff61708c68805878447a0ffe987fecb43e3677f4601d7f727df6d66d9d81bd1"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s Tremfya gains EC marketing authorisation for ulcerative colitis",
    "summary": "The approval of the therapy is underpinned by QUASAR programme data.",
    "url": "https://finnhub.io/api/news?id=2d289e10d0710cae71ff1c62fb3bf14c1d62c9eea0c5e52021e5e0a61eeeff0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745851449,
      "headline": "J&J’s Tremfya gains EC marketing authorisation for ulcerative colitis",
      "id": 134115087,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The approval of the therapy is underpinned by QUASAR programme data.",
      "url": "https://finnhub.io/api/news?id=2d289e10d0710cae71ff1c62fb3bf14c1d62c9eea0c5e52021e5e0a61eeeff0b"
    }
  },
  {
    "ts": null,
    "headline": "CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug",
    "summary": "Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.",
    "url": "https://finnhub.io/api/news?id=0caee023cfe0467db34f5b9620b5368cc483d21ada3446d2787b5d5d5114aa61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745850296,
      "headline": "CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug",
      "id": 134115088,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.",
      "url": "https://finnhub.io/api/news?id=0caee023cfe0467db34f5b9620b5368cc483d21ada3446d2787b5d5d5114aa61"
    }
  },
  {
    "ts": null,
    "headline": "Google Parent Alphabet to Sell High-Grade Corporate Bonds",
    "summary": "(Bloomberg) -- Alphabet Inc., parent company of Google, is offering about $4 billion of US high-grade corporate bonds on Monday, according to people with knowledge of the matter.Most Read from BloombergNewsom Says California Is Now the World’s Fourth-Biggest EconomyAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryLos Angeles Downgraded to AA- by S&P Due to Budget WoesUS Cricket Deepens Bet on Texas With HQ Shift From CaliforniaThe Last Thing US Transit Agencies Should Do NowThe",
    "url": "https://finnhub.io/api/news?id=16bd3b8ef72006e1dc3ae2fa3caf92d9d49f9b9759e06563a2e6ae3348f8b800",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745844100,
      "headline": "Google Parent Alphabet to Sell High-Grade Corporate Bonds",
      "id": 134114976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Alphabet Inc., parent company of Google, is offering about $4 billion of US high-grade corporate bonds on Monday, according to people with knowledge of the matter.Most Read from BloombergNewsom Says California Is Now the World’s Fourth-Biggest EconomyAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryLos Angeles Downgraded to AA- by S&P Due to Budget WoesUS Cricket Deepens Bet on Texas With HQ Shift From CaliforniaThe Last Thing US Transit Agencies Should Do NowThe",
      "url": "https://finnhub.io/api/news?id=16bd3b8ef72006e1dc3ae2fa3caf92d9d49f9b9759e06563a2e6ae3348f8b800"
    }
  }
]